UN report: Older people at particular risk from climate change
"Heat waves are among the most frequent and deadly impacts of climate change, along with floods and shrinking ice cover,' said Inger Andersen, the UNEP's executive director. 'We must be prepared for the risks these impacts pose, especially for society's most vulnerable, including older persons.'
Annual heat-related deaths among older people have risen by around 85% since the 1990s.
Older people - especially those suffering from chronic illnesses or frailty and with limited mobility - are particularly susceptible to heat-related health problems, including respiratory, cardiovascular and metabolic diseases. The mortality rate is also higher in this group.
The combination of heat and high humidity, which is already being observed during heatwaves in some tropical regions, is particularly dangerous for elderly people.
Warming cities are also increasingly problematic, especially as the urban population is increasing worldwide.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
36 minutes ago
- Yahoo
Next-Gen Heart Trial and Raised Outlook Might Change the Case for Investing in TransMedics (TMDX)
TransMedics Group, Inc. recently received conditional FDA approval to begin its Next-Generation OCS ENHANCE Heart trial, the largest heart transplant preservation study to date, and reported strong quarterly results with increased full-year revenue guidance. This combination of clinical and financial milestones highlights TransMedics' efforts to expand both the use and market reach of its organ transplant technology. We'll assess how the launch of this major clinical trial could impact TransMedics' broader investment outlook and future growth drivers. These 14 companies survived and thrived after COVID and have the right ingredients to survive Trump's tariffs. Discover why before your portfolio feels the trade war pinch. TransMedics Group Investment Narrative Recap To be a TransMedics Group shareholder, you need to believe that advances in organ preservation technology and successful clinical outcomes will drive broader adoption, fueling long-term growth. The FDA's conditional approval for the Next-Generation OCS ENHANCE Heart trial is an important development that could influence short-term sentiment but does not fundamentally change the biggest immediate catalyst: further clinical validation of OCS platforms; nor does it remove the largest risk, which remains the possibility of underwhelming trial results or advances from competitors. Among the company's recent updates, the revised full-year 2025 revenue guidance, now set at US$585 million to US$605 million, stands out. This more optimistic outlook directly relates to expanded clinical activity and increasing OCS system adoption, reinforcing the importance of future clinical milestones as potential inflection points for both revenue acceleration and investor confidence. On the other hand, investors should be aware of challenges if next-generation OCS trials fail to meet… Read the full narrative on TransMedics Group (it's free!) TransMedics Group is projected to reach $913.8 million in revenue and $151.1 million in earnings by 2028. This outlook assumes annual revenue growth of 19.8% and nearly doubles earnings, with an increase of $79.4 million from the current $71.7 million. Uncover how TransMedics Group's forecasts yield a $142.29 fair value, a 12% upside to its current price. Exploring Other Perspectives Nine fair value estimates from the Simply Wall St Community range from US$65.24 to US$308.09 per share. With heightened expectations pinned to new clinical trials, these wide opinions reflect just how differently you and other investors may assess future business risks and opportunities. Explore 9 other fair value estimates on TransMedics Group - why the stock might be worth over 2x more than the current price! Build Your Own TransMedics Group Narrative Disagree with existing narratives? Create your own in under 3 minutes - extraordinary investment returns rarely come from following the herd. A great starting point for your TransMedics Group research is our analysis highlighting 3 key rewards that could impact your investment decision. Our free TransMedics Group research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate TransMedics Group's overall financial health at a glance. Interested In Other Possibilities? Our top stock finds are flying under the radar-for now. Get in early: The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 20 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement. The latest GPUs need a type of rare earth metal called Terbium and there are only 26 companies in the world exploring or producing it. Find the list for free. The end of cancer? These 26 emerging AI stocks are developing tech that will allow early identification of life changing diseases like cancer and Alzheimer's. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include TMDX. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
4 hours ago
- Yahoo
This drug can turn your blood into mosquito poison
Mosquitoes may have just met their match: A prescription drug already used to treat a rare genetic disease in humans can make a person's blood poisonous to insecticide-resistant, malaria-carrying mosquitoes. New research published on July 31, 2025, in Parasites & Vectors found that the same drug, nitisinone, can even kill mosquitoes that simply land on a surface sprayed with the chemical. The findings could open up new avenues to stop the spread of diseases like malaria and dengue, especially as more mosquito populations evolve to become resistant to traditional prevention methods. Whether people will willingly offer their bodies as mosquito blood bait, though, remains less clear. 'This study demonstrates that nitisinone exhibits a novel mode of action distinct from current [insecticides] by specifically targeting blood digestion processes,' the researchers write. Toxic blood Nitisinone is a pharmaceutical drug derived from a toxin naturally found in the Australian bottlebrush plant. Initially intended for use as an herbicide, the drug targets a nonessential amino acid called tyrosine, which plays an important role in producing and regulating hormones. Research in the late 20th century discovered that nitisinone was also effective in treating tyrosinemia type I and alkaptonuria, two rare genetic disorders that impair the body's ability to metabolize tyrosine. The FDA approved the drug in 2002 to treat those suffering from these conditions. But the same process that helps humans metabolize tyrosine also acts as a kind of amino acid sabotage to blood-sucking mosquitoes. Earlier this year, researchers writing in Science Translational Medicine found that mosquitoes that fed on the blood of humans taking nitisinone died within several hours of their meal. And while patients typically take nitisinone in relatively high doses, the researchers found that the toxic effect on mosquitoes occurs even when the drug is taken in substantially lower amounts. The poisoning process blocks an enzyme mosquitoes need to process proteins and amino acids in blood. Introducing nitisinone disrupts their 'bloodmeal digestion' and effectively clogs the mosquitoes' digestive system. In other words, the drug takes mosquitoes' ability to convert protein from human blood—and turns it against them. But the new findings in the Parasites & Vectors study suggest this same poisoning process could also work without having to administer nitisinone to humans. In their tests, researchers exposed several mosquito species to surfaces treated with nitisinone and four other HPPD inhibitors, both before and after the insects fed on a blood sample. According to the study, the mosquitoes absorbed nitisinone through their feet. Over the course of several hours, nitisinone had similar poisoning effects on mosquitoes as it did on those that drank the treated blood. In every case, exposure to nitisinone caused paralysis. All of the affected mosquitoes also darkened in color. While researchers are confident the process works, they still aren't exactly sure why. It remains unclear how nitisinone is absorbed through the mosquitoes' feet or why the other three similar drugs didn't produce the same deadly results. 'This project proved how important it is to think outside the box,' paper senior author and Honorary Research Fellow at LSTM Lee Haines said in a statement. A new tool to fight resistant skeeters As anyone who's tried—and failed—to mosquito-proof their yard with bug spray knows, it doesn't always work. And that's not just a matter of user error: Insecticide-resistant mosquito variants are becoming increasingly common around the world. Some studies suggest that mosquitoes capable of surviving prolonged exposure to current insecticides make up as much as 30 percent of the population. Research from the World Health Organization estimates that mosquitoes resistant to at least one insecticide have been detected in over 90 percent of countries where malaria is considered endemic. That's a troubling trend, especially considering malaria still infects an estimated 263 million people every year, nearly 600,000 of which end up dying from it. Related Mosquito Stories How to build a mosquito kill bucket What would a world without mosquitoes look like? 11 home remedies for mosquito bites to battle the itch Mosquitoes can barely see–but a male's vision perks up when they hear a female Can a bold new plan to stop mosquitoes catch on? The nitisinone findings offer an encouraging sign that effective alternatives for controlling mosquito populations may already exist. Evidence that mere exposure to surfaces treated with the drug is an effective skeeter killer suggests nitisinone could potentially be applied to nets or other bedding materials as an alternative to traditional insecticides. 'Working with a drug like nitisinone, and its versatility, bodes well for creating new products to combat mosquitoes,' Haines said. 'The fact that it effectively kills insecticide-resistant mosquitoes could be a game-changer in areas where resistance to current insecticides is causing public health interventions to fail.' Humans certainly aren't lacking in creativity when it comes to killing mosquitoes. Genetically modified mosquitoes designed only to produce male offspring have been released in certain parts of the U.S. with the hopes that they will reduce overall populations. In Hawaii, the firm Drone Amplified recently dropped dozens of biodegradable, lab grown mosquito pods over forest areas in effort to combat the area's invasive mosquito population. More recently, scientists in China released cannibal 'elephant mosquitos' that are intended to eat the larvae of their smaller cousins capable of carrying dengue. Those more extravagant solutions aren't always necessary though. In the future, households looking to keep the buzzing at bay might simply be able to rub so nitisinone on their screens. Solve the daily Crossword
Business Wire
5 hours ago
- Business Wire
Pacific Prime Won Healthcare Insurance Insight Award by MediLink-Global
BUSINESS WIRE)-- Pacific Prime, a leading intermediary of international health insurance and employee benefits solutions, is proud to announce that it has been honored with the prestigious Healthcare Insurance Insight Award from MediLink-Global. The award ceremony took place on July 21, 2025, at the luxurious Park Hyatt Beijing. This award is a testament to Pacific Prime's unwavering commitment to a customer-centric approach. By leveraging data and feedback, the company continues to refine its services to better meet client needs. The recognition from MediLink-Global highlights Pacific Prime's dedication to delivering exceptional value and service to its clients. Head of Strategic Development of Pacific Prime's China Office, Wallace Yang, was also one of only two recipients nationwide to win the "MediLink-Global High-End Medical Service - Extraordinary Master" Award during the ceremony. This accolade recognizes Mr. Yang's leadership and commitment to setting industry standards in the high-end medical service sector. Ms. Xu Jingjing, Sales Director of the Southern Region at MediLink-Global, expressed her admiration for Pacific Prime, stating, ' Pacific Prime is a valued long-term partner. They have provided us with many ideas and innovative directions with their extensive experience and keen insights into the global insurance market. We firmly believe that partnering with a visionary company like Pacific Prime will drive us to remain at the forefront of future changes in the market. ' Mr. Pierre Morin, Global Sales Director of Pacific Prime, expressed gratitude for this prestigious award, 'This award from MediLink-Global not only affirms our past collaborations but also offers a positive outlook for the future. Pacific Prime will continue to uphold our professionalism and innovative spirit, closely observe global insurance market trends, and provide individuals and corporate clients with health experiences that are even more thoughtful and comprehensive.' About MediLink-Global MediLink (Beijing) Technology Service Co., Ltd. (MediLink-Global) is a leading third-party service provider specializing in health insurance management. Established in 2005, it has grown into a significant player in the health management service sector, boasting a network of nearly 3,000 high-end private hospitals worldwide. To learn more about MediLink-Global, please visit: About Pacific Prime Established in 2000, Pacific Prime Group is an award-winning global insurance intermediary and employee benefits specialist that offers individual and corporate insurance solutions. The group has over 1,000 employees and 15 offices worldwide, including Hong Kong, Singapore, China, Thailand, Malaysia, the UAE, Indonesia, the UK, the US, Mexico, the Philippines, and Australia. To learn more about Pacific Prime, please visit:
